Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
about
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsClinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
P2860
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
@en
type
label
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
@en
prefLabel
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
@en
P2093
P2860
P1433
P1476
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
@en
P2093
Allison S Betof
Anita Giobbie-Hurder
Donald P Lawrence
Douglas B Johnson
Krista Rubin
Romany A N Johnpulle
Ryan D Nipp
Ryan J Sullivan
Samuel M Rubinstein
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0450
P577
2017-05-05T00:00:00Z